BlackRock
RXRX icon

BlackRock’s Recursion Pharmaceuticals RXRX Stock Holding History

BlackRock’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$185M Buy
50,304,691
+7,112,385
+16% +$23.7M ﹤0.01% 1843
2026
Q1 		$133M Buy
43,192,306
+4,325,527
+11% +$16.7M ﹤0.01% 1928
2025
Q4 		$159M Buy
38,866,779
+7,127,014
+22% +$35.3M ﹤0.01% 1835
2025
Q3 		$155M Buy
31,739,765
+3,368,702
+12% +$17.7M ﹤0.01% 1819
2025
Q2 		$144M Buy
28,371,063
+4,864,474
+21% +$23.9M ﹤0.01% 1817
2025
Q1 		$124M Buy
23,506,589
+69,953
+0.3% +$510K ﹤0.01% 1865
2024
Q4 		$158M Buy
23,436,636
+2,693,839
+13% +$18.1M ﹤0.01% 1796
2024
Q3 		$137M Buy
20,742,797
+3,432,635
+20% +$24.6M ﹤0.01% 1900
2024
Q2 		$130M Buy
17,310,162
+4,989,127
+40% +$43.5M ﹤0.01% 1876
2024
Q1 		$123M Sell
12,321,035
-72,837
-0.6% -$811K ﹤0.01% 1951
2023
Q4 		$122M Buy
12,393,872
+536,918
+5% +$3.83M ﹤0.01% 1964
2023
Q3 		$90.7M Buy
11,856,954
+237,527
+2% +$2.37M ﹤0.01% 2050
2023
Q2 		$86.8M Buy
11,619,427
+987,570
+9% +$6.91M ﹤0.01% 2139
2023
Q1 		$70.9M Sell
10,631,857
-35,767
-0.3% -$284K ﹤0.01% 2227
2022
Q4 		$82.2M Buy
10,667,624
+900,584
+9% +$8.83M ﹤0.01% 2135
2022
Q3 		$104M Buy
9,767,040
+1,525,258
+19% +$15.4M ﹤0.01% 1936
2022
Q2 		$67.1M Buy
8,241,782
+1,534,025
+23% +$10.3M ﹤0.01% 2291
2022
Q1 		$48M Sell
6,707,757
-54,927
-0.8% -$584K ﹤0.01% 2618
2021
Q4 		$116M Buy
6,762,684
+4,995,020
+283% +$94M ﹤0.01% 2117
2021
Q3 		$40.7M Buy
1,767,664
+323,586
+22% +$9.17M ﹤0.01% 2793
2021
Q2 		$52.7M Buy
+1,444,078
New +$42.7M ﹤0.01% 2665

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

BlackRock's RXRX Position: Q2 2026 in Review

BlackRock increased its Recursion Pharmaceuticals (RXRX) stake by 16% in Q2 2026, buying an estimated $23.7M and bringing the position to 50,304,691 shares worth $185M. The position accounts for ﹤0.01% of the portfolio, ranked #1843.

BlackRock first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. 341 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • BlackRock held 50,304,691 shares of Recursion Pharmaceuticals worth $185M as of Q2 2026.
  • BlackRock bought 7,112,385 Recursion Pharmaceuticals shares in Q2 2026, an estimated $23.7M.
  • Recursion Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1843 holding.
  • BlackRock first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • 341 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.